Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Sutro Biopharma Reports Third Quarter 2018 Financial Results

Press Releases

Sutro Biopharma Reports Third Quarter 2018 Financial Results — STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma — STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN...

Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

Press Releases

Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer Initiation of Phase 1 Trial Planned for Early 2019 Company’s Second...

Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors

News, Press Releases

Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors Sharp to Bring Additional Financial Expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., Nov. 8, 2018 — Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that Shalini Sharp, Chief...

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

Press Releases

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma A New Generation of Precisely Engineered CD74-Targeting ADC SOUTH SAN FRANCISCO, Oct. 12, 2018– Sutro Biopharma, Inc. (NASDAQ: STRO),has been granted Orphan Drug...

Sutro Biopharma Announces $85.0 Million Initial Public Offering

Press Releases

Sutro Biopharma Announces $85.0 Million Initial Public Offering South San Francisco, California – September 26, 2018.  Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated...

Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief

Press Releases

Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief SOUTH SAN FRANCISCO, Sept. 12, 2018 – Sutro Biopharma, Inc., has appointed Stephen Worsley as chief business officer and has named Linda Fitzpatrick to the newly-created...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.